Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/12/2025: GDTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.1% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.89M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.31 | 52 Weeks Range 1.20 - 4.05 | Updated Date 06/30/2025 |
52 Weeks Range 1.20 - 4.05 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -530.32% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -24.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23354576 | Price to Sales(TTM) 53.42 |
Enterprise Value 23354576 | Price to Sales(TTM) 53.42 | ||
Enterprise Value to Revenue 428.61 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11540000 | Shares Floating 3593787 |
Shares Outstanding 11540000 | Shares Floating 3593787 | ||
Percent Insiders 68.86 | Percent Institutions 0.32 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CytoMed Therapeutics Limited Ordinary Shares
Company Overview
History and Background
CytoMed Therapeutics Limited is a Singapore-based biotechnology company focused on developing novel immunotherapies to treat a range of human cancers. It was founded in 2018 and has since focused on developing allogeneic cell-based immunotherapies.
Core Business Areas
- Cell-Based Immunotherapies: Development of allogeneic cell-based immunotherapies using engineered T cells and natural killer (NK) cells.
Leadership and Structure
Dr. Tan Wee Kiat is the CEO. The company has a board of directors with experience in biotechnology and finance. They operate with a research and development focused organizational structure.
Top Products and Market Share
Key Offerings
- CML-001: Allogeneic T cell immunotherapy targeting solid tumors. Currently in clinical trials. Competitors include companies developing CAR-T therapies for solid tumors, such as Novartis and Gilead. Market share data not currently available. Revenue from this product is currently $0 as it is still in trial.
- CML-002: Allogeneic NK cell immunotherapy targeting hematological malignancies. Currently in clinical trials. Competitors in the NK cell therapy space include Fate Therapeutics. Market share data not currently available. Revenue from this product is currently $0 as it is still in trial.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth, driven by advances in cell therapy and increasing prevalence of cancer. There is high competition among established pharmaceutical companies and emerging biotech firms.
Positioning
CytoMed is positioned as an emerging player in the allogeneic cell therapy space. Their focus on allogeneic therapies provides potential advantages in terms of scalability and cost-effectiveness compared to autologous therapies.
Total Addressable Market (TAM)
The global immunotherapy market is estimated at $250 Billion with projections to be $400B by 2028. CytoMed's focus on specific cancer types allows it to target niche markets within this larger space, with a position to obtain a small share of this TAM.
Upturn SWOT Analysis
Strengths
- Focus on allogeneic cell therapies
- Strong scientific team
- Proprietary cell engineering platform
- Novel approach to cancer immunotherapy
Weaknesses
- Limited funding compared to larger competitors
- Early stage clinical development
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
- Growing demand for effective cancer immunotherapies
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- FATE
- NK
- NVS
- GILD
Competitive Landscape
CytoMed faces competition from larger, more established companies in the immunotherapy space. Its competitive advantage lies in its allogeneic cell therapy platform and focus on specific cancer indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent establishment.
Future Projections: Future growth is dependent on the successful development and commercialization of its immunotherapy candidates.
Recent Initiatives: Advancement of CML-001 and CML-002 through clinical trials, and expansion of its research pipeline.
Summary
CytoMed Therapeutics is a developing biotechnology company focused on novel allogeneic cell-based immunotherapies. The company's strength lies in its novel approach to cancer treatment, however as a small firm it faces significant financial challenges. Positive clinical trial results are critical for their growth. The company needs to continue to focus on strategic partnerships to mitigate market competion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://w2.cytomed.sg |
Full time employees 43 | Website https://w2.cytomed.sg | ||
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.